Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Status der Studie

» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien

Alle Linien

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (Aktiv)

BI 907828
This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (Aktiv)

Tumordiagnostische Präzisionsimmunoonkologie und somatisches Targeting rational rational for you (TAPISTRY) Phase II - Plattformversuch (Aktiv)

A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors (Aktiv)

A Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (Aktiv)

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (Aktiv)

CodeBreak 101
A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (Aktiv)

GSK209012 (Zenyth-Eso)
Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (Aktiv)

IMbrella B
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) (Aktiv)

Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (Aktiv)

Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)

This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. (Aktiv)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)

MR Linac
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)

Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)

NOA-26 - IT-PD1
Intrathekale Anwendung von PD1-Antikörpern bei metastasierten soliden Tumoren mit leptomeningealer Erkrankung (Aktiv)

RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)

Simultane integrierte Protektion zur Schonung der kritischen Organe in der Nähe von Läsionen bei der Körperstereotaxie (Aktiv)

Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)

Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)


Abbvie M23-385
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. (Aktiv)

Keynote-158, MK3475-158
Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)

A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)

Zweitlinie oder später

A Phase 1/2a Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors (Aktiv)

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (Aktiv)

Amgen 20210023
Eine Phase-1/1b/2-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von AMG 193 allein und in Kombination mit Docetaxel bei Patienten mit fortgeschrittenen soliden MTAP-null-Tumoren (Aktiv)

BI 1479-0001
An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations (Aktiv)

BMS CA052-002
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors (Aktiv)

A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)

BoB Module 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)

Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)

Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment as monotherapy or in combination treatment (Aktiv)

study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)

Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab (Aktiv)

CRAFT Studie (PMO-1602)
The NCT-PMO-1602 Phase II Trial (Aktiv)

CatalYm CTL-002-001
First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)

Phase-I-Studie zur Untersuchung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von Tinostamustine, einem First-in-Class alkylierenden HDACi-Fusionsmolekül, bei rezidivierenden/refraktären hämatologischen Malignomen Eine Phase-1/2-Studie zur Untersuchung der Sicherheit, Pharmakokinetik und Wirksamkeit von EDO-S101, einem erstklassigen HDACi-Fusionsmolekül (Alkylating Histone Deacetylase Inhibition) bei Patienten mit fortgeschrittenen soliden Tumoren Untersuchung der Sicherheit, Phar (Aktiv)

I3Y-MC-JPCS Abemaciclib
A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors (Aktiv)

ICT01-102 (EVICTION-2)
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors. (EVICTION-2) (Aktiv)

IGNYTE (RPL-001-16)
Eine offene, multizentrische Phase-1/2-Studie mit RP1 als Einzelwirkstoff und in Kombination mit PD1-Blockade bei Patienten mit soliden Tumoren (Aktiv)

IMA 201-101
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (Aktiv)

IMA 401-101
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)

IMA402 (bispecific T cell engaging receptor molecule)
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors (Aktiv)

INFORM2-NivEnt (NCT-2017-0516)
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)

Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)

Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases (Aktiv)

Imcheck ICT01-101 (EVICTION)
First-in-Human Study of ICT01 in Patients With Advanced Cancer (Aktiv)

Immatics IMA 203-101
TCR-engineered T Cells in Solid Tumors (Aktiv)

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (Aktiv)

A Phase Ib/II, multicenter, open-label dose escalation and expansion platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation (Aktiv)

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)

A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)

Study of Pembrolizumab (MK-3475) in Children (Aktiv)

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)

Eine Phase-2-Studie mit Pembrolizumab in Kombination mit Olaparib bei Teilnehmern mit vorbehandeltem, Homologe Rekombinationsreparatur-Mutation (HRRm) oder Homologe Rekombinationsdefizienz (HRD) positivem fortgeschrittenem Krebs (Aktiv)

Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The primary objective is to show superior disease control rate in patients with HRR-deficient tumors treated with olaparib and trabectedin compared to treatment according to current guidelines (physician's choice) (Aktiv)

Olaparib / AstraZeneca
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours (Aktiv)

PH-IL12L19L19-01/19 -Dodekin
Safety and Early Signs of Efficacy of IL12-L19L19. (Aktiv)

Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)

Eine offene Phase-II-Multikohorten-2-Stufen-Studie zur Bewertung der Wirksamkeit und Sicherheit von Regorafenib in Kombination mit Tislelizumab bei Patienten mit ausgewählten Mismatch-Reparatur profizienten/mikrosatellitenstabilen vorbehandelten soliden Krebsarten (Aktiv)

Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors (Aktiv)

Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (Aktiv)

Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (Aktiv)

TKnife TK-8001
A Phase 1/2, First-in-Human, Open-Label, Two Part Clinical Trial of TK-8001 (MAGE-A1--Directed TCR Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy (Aktiv)

VB N-02
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (Aktiv)

Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit |